Hydrolyzed tetravalent metal salts and methods of biofilm inhibition

Patent metadata

Field	Value
Publication number	US-10835556-B2
Application number	US-201916288694-A
Country	US
Kind code	B2
Filing date	Feb 28, 2019
Priority date	Feb 28, 2018
Publication date	Nov 17, 2020
Grant date	Nov 17, 2020

Abstract

Described herein are hydrolyzed tetravalent salts and formulations thereof that can be used to inhibit a biofilm. Also described herein are uses of the hydrolyzed tetravalent salts and formulations thereof to inhibit a biofilm and/or treat biofilm infection.

First claim

I claim:

1. A formulation comprising:
an effective amount of a hydrolyzed tetravalent metal salt nanoparticle that inhibits biofilm formation, wherein the hydrolyzed tetravalent metal salt is a hydrolysis product of a Ce(IV) salt, a Zr(IV) salt, or a Ti(IV) salt.

2. The formulation of claim 1 , wherein the hydrolyzed tetravalent metal salt is a hydrolysis product of Ce(IV) salt.

3. The formulation of claim 1 , wherein the hydrolyzed tetravalent metal salt is CeO 2 .

4. The formulation of claim 3 , wherein the nanoparticles have an average hydrodynamic radius of about 2 nm to about 10 nm.

5. The formulation of claim 1 , further comprising an additional metal salt selected from the group consisting of: salts of Ca(II), Sr(II), Ba(II), Zn(II), Cu(II), Be(II), Ni(II), Fe(II), Co(II), Mn(II), Cr(II), V(II), Ti(II), Sc(II), Cd(II), Hg(II), cacodylic acid (As) sodium salt, and any combination thereof.

6. A method of inhibiting a biofilm in a subject in need thereof, the method comprising:
administering to the subject in need thereof an amount of a pharmaceutical formulation comprising:
the formulation of claim 1 ; and
a pharmaceutically acceptable carrier.

7. The method of claim 6 , wherein the pharmaceutical formulation further comprises an additional metal salt selected from the group consisting of: salts of Ca(II), Sr(II), Ba(II), Zn(II), Cu(II), Be(II), Ni(II), Fe(II), Co(II), Mn(II), Cr(II), V(II), Ti(II), Sc(II), Cd(II), Hg(II), cacodylic acid (As) sodium salt, and any combination thereof.

8. A medical device comprising:
one or more surfaces partially or completely coated with the formulation of claim 1 .

9. The medical device of claim 8 , wherein the formulation further comprises an additional metal salt selected from the group consisting of: salts of Ca(II), Sr(II), Ba(II), Zn(II), Cu(II), Be(II), Ni(II), Fe(II), Co(II), Mn(II), Cr(II), V(II), Ti(II), Sc(II), Cd(II), Hg(II), cacodylic acid (As) sodium salt, and any combination thereof.

10. The formulation of claim 1 , wherein the formulation comprises an oral formulation.

11. The formulation of claim 10 , wherein the formulation comprises a foam, spray, lozenge, pastille, mouth wash, mouth rinse, or paste.

12. The formulation of claim 10 , wherein the formulation comprises nanoparticles of CeO 2 having an average hydrodynamic radius of about 2 nm to about 10 nm.

13. The formulation of claim 10 , wherein the hydrolyzed tetravalent metal salt has a dosage of from about 1 picogram to 10 grams.

14. The formulation of claim 1 , wherein the formulation further comprises a pharmaceutically acceptable carrier.

15. The formulation of claim 14 , wherein the pharmaceutically acceptable carrier comprises water, a salt solution, an alcohol, gum arabic, a vegetable oil, a benzyl alcohol, a polyethylene glycol, gelatin, a carbohydrate, magnesium stearate, talc, silicic acid, a viscous paraffin, a perfume oil, a fatty acid ester, a hydroxy methylcellulose, or polyvinyl pyrrolidone.

16. The formulation of claim 14 , wherein the pharmaceutically acceptable carrier comprises a carbohydrate.

17. The formulation of claim 1 , wherein the nanoparticle is coated.

18. The formulation of claim 17 , wherein the coating comprises a cellulose polymer, polyvinyl acetate phthalate, an acrylic acid polymer and copolymer, or a methacrylic resin.

Assignees

• Univ Illinois
• Board Of Trustees Of The Univ Of Illinois

Inventors

• Pesavento Russell

Classifications

• A61L27/54 Primary

  Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)} · CPC title

• A61L2300/102

  Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates · CPC title

• A61L2300/606

  Coatings · CPC title

• A61L31/16

  Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)} · CPC title

• A61L2300/404

  Biocides, antimicrobial agents, antiseptic agents · CPC title